In animal models of non-alcoholic fatty liver disease, the expression of acid sphingomyelinase is increased [41], and whereas total hepatic ceramides are not altered, a change occurs in the relative abundance of ceramides, from higher levels of C24 ceramides to higher levels of C16 ceramides [41]. This evidence concerns the gene SMPD1 and metabolic dysfunction-associated steatotic liver disease.